Published in Nat Chem Biol on December 01, 2005
TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 2.17
Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol (2008) 1.42
Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem (2009) 1.10
The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells. PLoS One (2009) 0.91
Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol (2011) 0.90
A foldamer-dendrimer conjugate neutralizes synaptotoxic β-amyloid oligomers. PLoS One (2012) 0.84
Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells. ACS Chem Biol (2012) 0.83
Rigid multivalent scaffolds based on adamantane. J Org Chem (2008) 0.80
Assembling ligands in situ using bioorthogonal boronate ester synthesis. Chem Biol (2010) 0.78
Synthesis of trifunctional cyclo-β-tripeptide templates. Beilstein J Org Chem (2012) 0.75
CD40-CD40L interaction in immunity against protozoan infections. J Biomed Biotechnol (2007) 0.75
Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant. PLoS One (2017) 0.75
IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell (2007) 7.74
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol (2001) 4.87
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Chemistry of carbon nanotubes. Chem Rev (2006) 4.30
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest (2002) 4.14
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A (2006) 3.86
The molecular architecture of the TNF superfamily. Trends Biochem Sci (2002) 3.39
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Science and technology roadmap for graphene, related two-dimensional crystals, and hybrid systems. Nanoscale (2015) 2.86
Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev (2006) 2.79
The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem (2002) 2.75
Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2006) 2.75
Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun (Camb) (2003) 2.73
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68
T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature (2009) 2.59
Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat Nanotechnol (2007) 2.57
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A (2010) 2.45
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood (2008) 2.44
Functionalized carbon nanotubes for plasmid DNA gene delivery. Angew Chem Int Ed Engl (2004) 2.36
TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med (2008) 2.33
Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem Biol (2003) 2.28
Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett (2006) 2.24
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res (2007) 2.12
TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol (2008) 2.11
Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med (2013) 2.09
BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol (2006) 2.09
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res (2009) 2.04
Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med (2005) 2.03
Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem (2005) 1.99
MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic (2009) 1.98
Binding and condensation of plasmid DNA onto functionalized carbon nanotubes: toward the construction of nanotube-based gene delivery vectors. J Am Chem Soc (2005) 1.97
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 1.93
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genet Med (2004) 1.89
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood (2007) 1.85
CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci (2009) 1.83
Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. Nat Med (2003) 1.75
Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum (2011) 1.75
TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J (2006) 1.73
Generation of the primary hair follicle pattern. Proc Natl Acad Sci U S A (2006) 1.72
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 1.67
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
NF-kappaB transmits Eda A1/EdaR signalling to activate Shh and cyclin D1 expression, and controls post-initiation hair placode down growth. Development (2006) 1.66
Length-dependent retention of carbon nanotubes in the pleural space of mice initiates sustained inflammation and progressive fibrosis on the parietal pleura. Am J Pathol (2011) 1.65
Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood (2008) 1.64
Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis. J Invest Dermatol (2006) 1.64
The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med (2002) 1.62
Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples. Genet Med (2002) 1.60
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res (2010) 1.59
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl (2005) 1.55
TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality. J Clin Invest (2006) 1.55
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 1.54
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
Ectodysplasin has a dual role in ectodermal organogenesis: inhibition of Bmp activity and induction of Shh expression. Development (2007) 1.53
Ectodysplasin A1 promotes placodal cell fate during early morphogenesis of ectodermal appendages. Development (2004) 1.53
Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol (2006) 1.52
Functionalized carbon nanotubes as emerging nanovectors for the delivery of therapeutics. Biochim Biophys Acta (2005) 1.52
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest (2008) 1.50
Cystic fibrosis screening: lessons learned from the first 320,000 patients. Genet Med (2004) 1.48
TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol (2004) 1.47
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
Detection of 677CT/1298AC "double variant" chromosomes: implications for interpretation of MTHFR genotyping results. Genet Med (2005) 1.44
Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe (2013) 1.41
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res (2003) 1.40
Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res (2011) 1.39
Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38
Mechanisms of genetically-based resistance to malaria. Gene (2010) 1.37
Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. PLoS One (2008) 1.36
Reciprocal repression between P53 and TCTP. Nat Med (2011) 1.35
TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev (2008) 1.35